JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy
  • Search
  • Contact Us
  • Public Perception of Obesity and Weight-Loss Drugs

  • Retatrutide Delivers Phase 3 Success and Signals Lilly’s Strategic Positioning

  • Semaglutide 7.2 mg Demonstrates Greater Weight Loss but Faces Market Challenges

  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

  • Teva Launches First Generic GLP-1 for Obesity

  • Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment

  • Wegovy Oral Pill Launches in United States

  • Wegovy Will Not Go OTC: What the Sources Actually Say

  • Wegovy: A New Horizon in Cardiovascular Risk Reduction for Obesity

  • Wegovy’s Lowest Dose Now Available in the U.S.

  • Zealand Pharma Pauses Development of Dapiglutide

  • Zealand Pharma Reports Phase 2 Results for Petrelintide

  • Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial

Page 2 of 2

  • 1
  • 2
  • You are here:  
  • Home
  • Tags
  • Obesity Treatment
 

JCS/T2D

We are advocates. We learn. We share. We inform.
Bringing clarity to type 2 diabetes, obesity care, health research, and the data behind them.

Content is provided for educational and informational purposes and is not medical advice.

Helpful Links

About Us
Contact Us
JCS Analytics

Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.